lovo-cel sickle
Selected indexed studies
- Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. (Am J Hematol, 2023) [PMID:36161320]
- Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States. (Pharmacoeconomics, 2024) [PMID:38684631]
- Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia. (Med Sci Monit, 2024) [PMID:38425279]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Impact of Different Definitions of Vaso-Occlusion on Efficacy Assessments in Sickle Cell Disease Clinical Trials. (2025) pubmed
- Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia. (2024) pubmed
- Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. (2023) pubmed
- Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States. (2024) pubmed
- Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review. (2024) pubmed
- Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review. (2024) pubmed
- Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access Challenges. (2025) pubmed
- Systemic medications for sickle cell disease and potential applications for sickle cell retinopathy. (2024) pubmed
- Implementing the Generalized Risk-Adjusted Cost-Effectiveness Model for Sickle Cell Disease: A Case Study. (2025) pubmed
- Clinical data comparison for FDA-approved gene therapies in sickle cell disease. (2025) pubmed